- Home
- NMT vs GNLX Comparison
NMT vs GNLX Comparison
Compare NMT & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- GNLX
- Stock Information
- Founded
- NMT 1993
- GNLX 2001
- Country
- NMT United States
- GNLX United States
- Employees
- NMT N/A
- GNLX N/A
- Industry
- NMT Finance/Investors Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- NMT Finance
- GNLX Health Care
- Exchange
- NMT Nasdaq
- GNLX Nasdaq
- Market Cap
- NMT 108.0M
- GNLX 128.0M
- IPO Year
- NMT N/A
- GNLX 2023
- Fundamental
- Price
- NMT $11.56
- GNLX $4.45
- Analyst Decision
- NMT
- GNLX Strong Buy
- Analyst Count
- NMT 0
- GNLX 4
- Target Price
- NMT N/A
- GNLX $17.75
- AVG Volume (30 Days)
- NMT 19.1K
- GNLX 146.1K
- Earning Date
- NMT 01-01-0001
- GNLX 11-13-2025
- Dividend Yield
- NMT 3.21%
- GNLX N/A
- EPS Growth
- NMT N/A
- GNLX N/A
- EPS
- NMT N/A
- GNLX N/A
- Revenue
- NMT N/A
- GNLX N/A
- Revenue This Year
- NMT N/A
- GNLX N/A
- Revenue Next Year
- NMT N/A
- GNLX N/A
- P/E Ratio
- NMT N/A
- GNLX N/A
- Revenue Growth
- NMT N/A
- GNLX N/A
- 52 Week Low
- NMT $9.05
- GNLX $1.99
- 52 Week High
- NMT $10.93
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- NMT 50.73
- GNLX 66.95
- Support Level
- NMT $11.58
- GNLX $4.17
- Resistance Level
- NMT $11.72
- GNLX $4.45
- Average True Range (ATR)
- NMT 0.11
- GNLX 0.30
- MACD
- NMT -0.01
- GNLX 0.02
- Stochastic Oscillator
- NMT 17.94
- GNLX 80.65
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.